Core Laboratories (CLB) EBT (2022 - 2026)

Core Laboratories has reported EBT for 5 years, with the latest figure at -$1.0 million in Q1 2026.

• For the quarter ending Q1 2026, EBT fell 155.32% year-over-year to -$1.0 million; the trailing twelve-month figure through Mar 2026 stood at $43.1 million (up 0.52% YoY), and the FY2025 full-year result was $45.9 million, down 0.63% from the prior year.
• EBT for Q1 2026 stood at -$1.0 million, down from $13.2 million in the prior quarter.
• The five-year high for EBT was $18.3 million in Q3 2025, with the low at -$1.0 million in Q1 2026.
• Historically, EBT has averaged $10.3 million across 5 years, with a median of $11.5 million in 2023.
• Annual changes were most pronounced in 2023 — EBT surged 75.18% — and 2026, when it slumped 155.32%.
• Core Laboratories' EBT stood at $12.5 million in 2022, then declined by 12.55% to $11.0 million in 2023, then advanced by 5.31% to $11.5 million in 2024, then increased by 14.53% to $13.2 million in 2025, then sank by 107.59% to -$1.0 million in 2026.
• The last three EBT figures came in at -$1.0 million (Q1 2026), $13.2 million (Q4 2025), and $18.3 million (Q3 2025), per Business Quant data.